There has been enough commotion caused by the COVID-19 pandemic, Now being into the 5th month of partial lockdown, Indians are expecting a speedy announcement of the vaccine launch. The various medical institutes have been in a race to develop the vaccine, which has altogether also manipulated the economies and decided the fate of the stock market.
The Novavax and Serum Institute of India Announce Development and Commercial Collaboration and announced a license agreement with Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, in low- and middle-income countries (LMIC) and India.
Novavax which is a late-stage biotechnological company developing next-generation vaccines for serious infections is strongly committed to ensuring the uniform and global supply of NVX-CoV2373 to low and middle-income countries that have been severely affected by the coronavirus, Serum Institute of India being the largest vaccine manufacturer in terms if doses delivered is the ideal partner to deliver and advance NVX-CoV2373 throughout Indian and LMIC countries as early as 2021, This partnership continues to build on our companies’ collaborative history.
The organization and the institute are partnering on clinical development, co-formulation, filling, and finishing and commercialization of NVX-CoV2373. Whereas Serum Institute will be responsible for regulatory submissions and marketing authorizations, and Novavax will provide vaccine antigen and Matrix?M adjuvant to the institute. Talking of finances, Novavax, and Serum will split the revenue from the sale of the product, net of agreed costs.
Adar Poonawalla, Chief Executive Officer of Serum Institute of India, said that the vaccine has significant potential to prevent COVID-19, given their experience with Novavax on the development of the vaccine for Malaria. The agreement will not only boost the distribution to LMIC but encourage the global supply of NVX-CoV2373 while complementing Novavax’s collaboration with Coalition for Epidemic Preparedness Innovations (CEPI).
Are we really getting NVX-CoV2373?
Future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are some of the forward-looking statements which are subject to risks and uncertainties that might cause the result to differ from what expressed earlier at a public forum.
What are the “risk-factors”?
The “risk-factors” are those which are mentioned under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, filed with Securities and Exchange Commission (SEC) and updated quarterly. Neither Novavx nor Serum Institute undertake any obligation to update or revise any of the statements as the business is subject to substantial risks and uncertainties.
Both the parties, as of now, have announced for the people to expect 1 billion doses for India and LMICs by leveraging the infrastructure provided by Serum Institute, as Serum also gains exclusive rights to commercialize in India and non-exclusive rights to commercialize in other LMIC countries. A non-biased, uniform, and global supply will be ensured amidst the deadly pandemic.
Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!